Formulation and evaluation of a particulate oral breast cancer vaccine

Chablani, Lipika; Tawde, Suprita A.; Akalkotkar, Archana; D'Souza, Cherilyn; Selvaraj, Periasamy; D’Souza, Martin J.

doi:10.1002/jps.23275

Cited by 22 publications

(23 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, AAL‐coupled microspheres were found to display preferential binding to the Peyer's patches of the follicle‐associated epithelium of the intestine . In keeping with the above, prophylactic oral administration of AAL‐bearing microparticles containing antigenic material in the form of tumor cell lysate has been previously demonstrated to induce high antibody titers and retard tumor growth in mice inoculated with various cancer cell lines …”

Section: Discussionmentioning

confidence: 55%

Development of a M cell‐targeted microparticulate platform, BSK02™, for oral immunization against the ovarian cancer antigen, sperm protein 17

Mattila¹,

Mirandola²,

Chiriva‐Internati

2018

J Biomed Mater Res

View full text Add to dashboard Cite

Although it only accounts for approximately 5% of all female cancer cases, ovarian cancer (OC) ranks as the fifth leading cause of death due to cancer in women. We have evaluated the potential of an orally administered microparticulate vaccine incorporating an immunodominant epitope peptide derived from the cancer/testis antigen sperm protein 17 (SP17) aberrantly expressed in OC, to retard the progression of the disease. The peptide antigen and the immune-stimulatory toll-like receptor 9 ligand CpG oligonucleotide were incorporated into spray dried microparticles composed of enteric and sustained release polymers together with the Aleuria aurantia lectin targeting microfold cells present in the gut-associated lymphoid tissue. These particles were administered via oral route to mice challenged week prior with SP17-expressing ID8 OC cells. Analysis of splenocytes harvested from vaccinated mice revealed strong activation of IFN-γ+/CD8+ lymphocytes in response to re-stimulation with the SP17 antigen. Moreover, vaccinated animals showed significant retardation of ascites/tumor volume in comparison to placebo-treated animals four weeks after the tumor challenge (p = 0.005). Taken together, our results suggest that vaccination against SP17 using orally administered microparticles could potentially be used as an effective consolidation strategy for OC patients with residual tumor or high probability for relapse following first-line treatments. © 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2018.

show abstract

Section: Discussionmentioning

confidence: 55%

Development of a M cell‐targeted microparticulate platform, BSK02™, for oral immunization against the ovarian cancer antigen, sperm protein 17

Mattila¹,

Mirandola²,

Chiriva‐Internati

2018

J Biomed Mater Res

View full text Add to dashboard Cite

show abstract

“…108 Several studies in our laboratory have proved the efficacy of oral microparticulate systems to elicit immune response against tumors. [109][110][111] The mechanism of immune system activation by the oral route is explained in the earlier section of this chapter. Our laboratory has also explored several targeting ligands that target M cells in order to enhance site-specific uptake of microparticles.…”

Section: Oral Particulate Prostate Cancer Vaccinesmentioning

confidence: 99%

“…Efficacy of vaccine microparticles could be seen with the tumor volume data (Figure 5.7). 109 Therapeutic applications of vaccine microparticles are currently being evaluated. The therapeutic efficacy of these vaccine microparticles is reportedly enhanced when given in combination with cytotoxic drug and adjuvants.…”

Section: Oral and Transdermal Breast Cancer Vaccinementioning

confidence: 99%

Trends in Nonparenteral Delivery of Biologics, Vaccines and Cancer Therapies

D’Souza

Gala

Ubale

et al. 2015

Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies

View full text Add to dashboard Cite

“…Langerhans cells are dendritic cells that activate T cells and induce a strong immune response and occupy around 20% of the skin's area. On the other hand, M-cells are the microfold cells, which act as sampling ports for any foreign entities encountered in the small intestine upon oral administration [18][19][20][21][22][23]. These M cells house various dendritic cells and immune cells in them.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of microparticulate ovarian cancer vaccine via transdermal route of delivery

Tawde¹,

Chablani

Akalkotkar

et al. 2016

Journal of Controlled Release

Self Cite

View full text Add to dashboard Cite

Ovarian cancer is the fifth most commonly occurring malignancy in women, with the highest mortality rate among all the gynecological tumors. Microparticulate vaccine can serve as an immunotherapeutic approach with a promising antigenic delivery system without a need for conventional adjuvants. In this study, a microparticulate vaccine using whole cell lysate of a murine ovarian cancer cell line, ID8 was prepared by spray drying. Further, the effect of interleukins (ILs) such as IL-2 and IL-12 was evaluated in a separate study group by administering them with vaccine particles to enhance the immune response. The vaccine microparticles were administered to C57BL/6 female mice via transdermal alone and in combination with the oral route. The transdermal vaccine was delivered using a metallic microneedle device, AdminPen™. Orally administered microparticles also included an M-cell targeting ligand, Aleuria aurantia lectin, to enhance the targeted uptake from microfold cells (M-cells) in Peyer's patches of small intestine. In case of combination of routes, mice were given 5 transdermal doses and 5 oral doses administered alternatively, beginning with transdermal dose. At the end of vaccination, mice were challenged with live tumor cells. Vaccine alone resulted in around 1.5 times tumor suppression in case of transdermal and combination of routes at the end of 15th week when compared to controls. Inclusion of interleukins resulted in 3 times tumor suppression when administered with transdermal vaccine and around 9 times tumor suppression for the combination route of delivery in comparison to controls. These results were further potentiated by serum IgG, IgG1 and IgG2a titers. Moreover, CD8+ T-cell, CD4+ T-cell and NK (natural killer) cell populations in splenocytes were elevated in case of vaccinated mice. Thus, vaccine microparticles could trigger humoral as well as cellular immune response when administered transdermally and via combination of route of delivery. However overall, vaccine administered with interleukins, via combination of route, was found to be the most efficacious to suppress the tumor growth and lead to a protective immune response.

show abstract

Formulation and evaluation of a particulate oral breast cancer vaccine

Cited by 22 publications

References 36 publications

Development of a M cell‐targeted microparticulate platform, BSK02™, for oral immunization against the ovarian cancer antigen, sperm protein 17

Development of a M cell‐targeted microparticulate platform, BSK02™, for oral immunization against the ovarian cancer antigen, sperm protein 17

Trends in Nonparenteral Delivery of Biologics, Vaccines and Cancer Therapies

Evaluation of microparticulate ovarian cancer vaccine via transdermal route of delivery

Contact Info

Product

Resources

About